ClinicalTrials.gg
CompletedNCT02468791Updated May 14, 2020

MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

A Phase 3 interventional study of Rituximab in Rheumatoid Arthritis, sponsored by Mabion SA. Completed at 51 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-14.

Sponsored by Mabion SA · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled May 2013, registered Jun 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
709
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
2nd of 63
709 · median 159
Started
2013
with 2 others
Phase 3
27 of 63
1 open now
Registered
51st of 63
by date

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 27 in phase 3, and was the 51st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and the reference product - MabThera® (rituximab) and to demonstrate comparative safety and tolerability of a single course of treatment of MabionCD20® and MabThera® in patients with moderate to severe active rheumatoid arthritis.

Read the detailed description

Subjects who meet the criteria for participation in this study receive 2 intravenous infusions of MabionCD20® or MabThera® with two weeks interval in combination with methotrexate and folic acid. After the treatment period, patients are followed for 24 weeks, in order to continue checking safety. Therefore, the total study lasts 48 weeks. There is a possibility to repeat treatment after 6 months of the first infusions if subject meets the retreatment criteria.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Autoimmune Diseases
  • Rituximab
  • Immune System Diseases
  • Joint Diseases
  • Rheumatic Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with active rheumatoid arthritis with disease duration minimum 6 months prior to screening visit
  • Patients who are naive to tumor necrosis factor (TNF) antagonists or any other monoclonal antibody therapies
  • Patients who have had an inadequate response to an adequate regimen of methotrexate

Exclusion criteria

Exclusion Criteria:

  • History of current rheumatic disease other than RA and current inflammatory joint disease other than RA
  • according to the MabThera SmPC and every serious coexisting diseases which, in the Investigator's opinion, would preclude subject participation
  • Positive tests for , surface antigen (HBsAg) Anti-HBc antibody, antibody
  • Prior treatment with rituximab, other anti-CD20 mAb, anti-TNF-alpha drug or any other monoclonal antibodies
  • Pregnancy or lactation or women planning to get pregnant during the course of the study and/or within 12 months post last study drug infusion
  • Allergic reaction or intolerance to rituximab, MabionCD20 or any of their components
  • Severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or previous treatment of any lymphocyte-depleting therapies
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
709 participants (actual)

Study arms

  • Experimental
    MabionCD20®

    A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.

    Drug: Rituximab

  • Active comparator
    MabThera®

    A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.

    Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients in each treatment group achieving the primary efficacy endpoint of a ≥ 20% improvement on the American College of Rheumatology score (ACR20) at Week 24.

    Time frame: 24 weeks

07

Study locations

51 sites
  • Clinical Centre Banja Luka Location Paprikovac
    Banja Luka, 78 000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, 88 000, Bosnia and Herzegovina
  • Clinical Centre University of Sarajevo
    Sarajevo, 71 000, Bosnia and Herzegovina
  • General Hospital "Dr. Abdulah Nakas"
    Sarajevo, 71 000, Bosnia and Herzegovina
  • University Clinical Centre Tuzla
    Tuzla, 75 000, Bosnia and Herzegovina
  • Carabs Medline Ltd
    Tbilisi, 0159, Georgia
  • Cardio-Reanimation Center Ltd
    Tbilisi, 0159, Georgia
  • Diagnostic Service ltd
    Tbilisi, 0159, Georgia
  • Tbilisi Heart and Vascular Clinic
    Tbilisi, 0159, Georgia
  • MediClub Georgia
    Tbilisi, 0160, Georgia
  • Medicore Ltd
    Tbilisi, 0186, Georgia
  • Medulla-Chemotherapy and Immunotherapy Clinic
    Tbilisi, 0186, Georgia
  • Centrum Miriada
    Białystok, 15-297, Poland
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Centrum Położnicze św Łukasza Sp.z.o.o
    Częstochowa, 42-202, Poland
  • NSZOZ Unica CR
    Dopiewo, 62-069, Poland
  • Wojewódzki Szpital Zespolony
    Elbląg, 82-300, Poland
  • Małopolskie Centrum Medyczne S.C.
    Kraków, 30-510, Poland
  • Szpital Uniwersytecki, Oddział Kliniczny Kliniki Chorób Wewnętrznych
    Kraków, 31-531, Poland
  • Szpital Specjalistyczny im. J. Dietla
    Kraków, 90-119, Poland
  • Ośrodek Badań Klinicznych
    Lublin, 20-022, Poland
  • REUMED
    Lublin, 20-582, Poland
  • NZOZ Lecznica MAK-MED. S.C.
    Nadarzyn, 05-830, Poland
  • Centrum Medyczne Nowa Sól
    Nowa Sól, 67-100, Poland
  • SOLUMED
    Poznań, 60-529, Poland
  • AL Klinika
    Poznań, 61-113, Poland
  • NZOZ Poradnia Leczenia Osteoporozy i Chorób Narządu Ruchu
    Stalowa Wola, 37-450, Poland
  • Zespół Opieki Zdrowotnej w Suchej Beskidzkiej
    Sucha Beskidzka, 34-200, Poland
  • Śląski Szpital Reumatologiczo-Rehabilitacyjny im. Generała Jerzego Ziętka
    Ustroń, 43-450, Poland
  • Medica Pro Familia Sp. z o.o. S.K.A
    Warsaw, 01-868, Poland
  • Linea Corporis Spółka z Ograniczoną Odpowiedzialnością
    Warszawa, 00-235, Poland
  • IRMED
    Warszawa, 01-157, Poland
  • Centrum Medyczne AMED
    Warszawa, 01-518, Poland
  • Instytut Reumatologii
    Warszawa, 02-637, Poland
  • KO-MED Centra Kliniczne
    Zamość, 22-400, Poland
  • Institute for Rheumatology - Belgrade
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Institute for treatment and rehabilitation "Niska Banja"
    Niska Banja, 18205, Serbia
  • Clinical center of Vojvodina, Clinic for medical rehabilitation
    Novi Sad, 21000, Serbia
  • Communal Medical Institution "City Clinical Hospital no 3"
    Chernivtsi, Ukraine
  • National Medical University, Chair of Internal Medicine based on Ivano-Frankivsk Central Clinical City Hospital
    Ivano-Frankivsk, Ukraine
  • Department of Cardiology and Functional Diagnostics, Kharkiv Medical Academy of Postgraduated Education
    Kharkiv,, Ukraine
  • Kharkiv City Clinical Hospital no 27
    Kharkiv, Ukraine
  • Regional Hospital Veterans of War
    Kharkiv, Ukraine
  • State Institute "L T Malaya Institute of Therapy of NAMS of Ukraine"
    Kharkiv, Ukraine
  • Administration of Medical Service and Rehabilitation of "ARTEM" State Holding Company
    Kyiv, Ukraine
  • National Scientific Center "M.D. STRAZHESKO INSTITUTE OF CARDIOLOGY, MAS OF UKRAINE"
    Kyiv, Ukraine
  • Chair of Internal Medicine no 2 of Ternopil State Medical University
    Ternopil, Ukraine
  • Uzhgorod Clinical Hospital of the Lviv Railways, Department of Therapy
    Uzhgorod, Ukraine
  • Clinical City Hospital no 7
    Zaporizhzhia, Ukraine
  • Zaporizhzhia Medical Academy of Postgraduate Education of Ministry of Health of Ukraine
    Zaporizhzhia, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in May 2017, 48 months.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 48 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2015
First posted
Jun 11, 2015
StartActual
May 2013
Primary completionActual
May 2017
CompletionActual
Oct 2017
Last update
May 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02468791
Lead sponsor
Mabion SA
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
May 2013
Primary completion
May 2017
Completion
Oct 2017
Last update
May 14, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion